Ted Yednock Ph.D.
Net Worth

Last updated:

What is Ted Yednock Ph.D. net worth?

The estimated net worth of Dr. Ted Yednock Ph.D. is at least $3,993,782 as of 15 Oct 2024. He owns shares worth $156,289 as insider, has earned $1,735,773 from insider trading and has received compensation worth at least $2,101,720 in Annexon, Inc..

What is the salary of Ted Yednock Ph.D.?

Dr. Ted Yednock Ph.D. salary is $525,430 per year as Executive Vice President, Chief Innovation Officer & Chairman of the Scientific Advisory Board in Annexon, Inc..

How old is Ted Yednock Ph.D.?

Dr. Ted Yednock Ph.D. is 67 years old, born in 1958.

What stocks does Ted Yednock Ph.D. currently own?

As insider, Dr. Ted Yednock Ph.D. owns shares in one company:

Company Title Shares Price per share Total value
Annexon, Inc. (ANNX) Executive Vice President, Chief Innovation Officer & Chairman of the Scientific Advisory Board 71,365 $2.19 $156,289

What does Annexon, Inc. do?

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.

ANNX logo
ANNX
Annexon, Inc.
$2.19

Ted Yednock Ph.D. insider trading

Annexon, Inc.

Dr. Ted Yednock Ph.D. has made 15 insider trades between 2021-2024, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 21,000 units of ANNX stock on 27 Dec 2023. As of 15 Oct 2024 he still owns at least 71,365 units of ANNX stock.

Transaction Date Security Shares Price per share Total value Source
Option
Stock Option (Right to Buy) 5,408 $1.85 $10,005
Option
Common Stock 5,408 $1.85 $10,005
Sale
Common Stock 5,408 $7.41 $40,073
Sale
Common Stock 4,500 $7.1 $31,950
Sale
Common Stock 5,500 $6.16 $33,880
Sale
Common Stock 5,500 $5.64 $31,020
Sale
Common Stock 5,500 $5.95 $32,725
Sale
Common Stock 1,106 $6.02 $6,658
Sale
Common Stock 2,604 $5.51 $14,348
Sale
Common Stock 1,810 $5.54 $10,027
Option
Stock Option (Right to Buy) 10,615 $1.41 $14,967
Option
Stock Option (Right to Buy) 10,385 $1.85 $19,212
Sale
Common Stock 21,000 $4.52 $94,962
Option
Common Stock 10,615 $1.41 $14,967
Option
Common Stock 10,385 $1.85 $19,212
Option
Common Stock 10,385 $1.85 $19,212
Option
Common Stock 10,615 $1.41 $14,967
Sale
Common Stock 21,000 $4.52 $94,962
Option
Common Stock 16,190 $20 $323,865
Option
Stock Option (Right to Buy) 15,000 $1.41 $21,150
Option
Common Stock 1,190 $5.11 $6,081
Option
Stock Option (Right to Buy) 16,190 $1.41 $22,828
Sale
Stock Option (Right to Buy) 16,190 $1.41 $22,828
Sale
Common Stock 16,190 $3.26 $52,779
Option
Stock Option (Right to Buy) 15,000 $1.41 $21,150
Option
Common Stock 15,000 $1.41 $21,150
Sale
Common Stock 15,000 $21.59 $323,775
Option
Stock Option (Right to Buy) 16,175 $3.26 $52,731
Sale
Common Stock 16,175 $29.24 $472,892
Option
Common Stock 16,175 $3.26 $52,731
Option
Stock Option (Right to Buy) 16,175 $3.26 $52,731
Sale
Common Stock 16,175 $29.24 $472,892
Option
Common Stock 16,175 $3.26 $52,731

Annexon key executives

Annexon, Inc. executives and other stock owners filed with the SEC:

  • Dr. Ted Yednock Ph.D. (67) Executive Vice President, Chief Innovation Officer & Chairman of the Scientific Advisory Board
  • Mr. Douglas Love J.D., Esq. (57) Chief Executive Officer, Pres & Director
  • Mr. Michael Overdorf M.B.A. (55) Executive Vice President & Chief Bus. Officer